Clinical Trials for Small Cell Lung Cancer

A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations and no prior systemic therapy for advanced disease, randomizing them to either sunvozertinib (DZD9008), a selective irreversible EGFR exon 20 inhibitor, or standard platinum-based doublet chemotherapy.

ClinicalTrials.gov ID: NCT05668988

A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

HealthScout AI summary: Enrolling treatment-naive adults with stage IV squamous or non-squamous NSCLC without actionable driver mutations, this trial compares ivonescimab (a bispecific antibody targeting PD-1 and VEGF) plus chemotherapy to pembrolizumab plus chemotherapy. Patients must have ECOG 0–1, at least one measurable noncerebral lesion, and available PD-L1 status, but enrollment is open regardless of PD-L1 expression.

ClinicalTrials.gov ID: NCT05899608

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

HealthScout AI summary: Adults with advanced or metastatic NSCLC harboring a KRAS G12C mutation and previously treated with one to three prior systemic therapies are randomized to receive either divarasib (an oral, highly selective, irreversible KRAS G12C inhibitor) or standard-of-care KRAS G12C inhibitors (sotorasib or adagrasib). Prior use of KRAS G12C inhibitors or presence of active CNS metastases excludes patients.

ClinicalTrials.gov ID: NCT06497556

Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors (The HARMONIC Study)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial is for never smoker patients with relapsed advanced primary adenocarcinoma of the lung, featuring actionable genomic alterations, who have progressed after tyrosine kinase inhibitor therapies. It examines the combination of the investigational multi-tyrosine kinase receptor inhibitor LP-300 with carboplatin and pemetrexed, compared to the standard carboplatin-pemetrexed regimen.

ClinicalTrials.gov ID: NCT05456256

A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adult patients with advanced solid tumors who have limited treatment options, evaluating the efficacy and safety of IBI363, a PD-1/IL-2α-bias bispecific antibody fusion protein targeting the PD-1/PD-L1 pathway and activating the IL-2 pathway to enhance tumor-specific T cell activity.

ClinicalTrials.gov ID: NCT06281678

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial targets patients with advanced ALK-positive non-small cell lung cancer who have not previously received specific treatments for NSCLC or ALK, comparing the efficacy of the novel ALK-selective tyrosine kinase inhibitor neladalkib (NVL-655) with alectinib in prolonging progression-free survival.

ClinicalTrials.gov ID: NCT06765109

RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with locally advanced or metastatic NSCLC harboring KRAS, NRAS, or HRAS mutations (codons 12, 13, or 61) and previously treated with anti-PD-(L)1 and platinum-based chemotherapy (but not RAS inhibitors or docetaxel) are randomized to receive either daraxonrasib, an oral pan-RAS(ON) inhibitor targeting active GTP-bound RAS, or standard docetaxel.

ClinicalTrials.gov ID: NCT06881784

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with advanced NSCLC who have progressed after standard therapies (including prior immunotherapy and platinum-based chemotherapy, or targeted therapy if actionable mutations are present) to receive HLX43, an investigational anti-PD-L1 antibody-drug conjugate linked to a topoisomerase I inhibitor, given intravenously every 3 weeks at two dose levels. Key exclusions include prior topoisomerase I inhibitor exposure, active CNS disease, or small cell/neuroendocrine/sarcomatoid histology.

ClinicalTrials.gov ID: NCT06907615

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with stage IV, non-squamous, metastatic NSCLC expressing PD-L1 (≥1%) without EGFR, ALK, or ROS1 mutations are randomized to receive either rilvegostomig—a bispecific PD-1/TIGIT antibody—or pembrolizumab, each in combination with platinum+pemetrexed chemotherapy, as first-line treatment. Prior immunotherapy is not permitted; patients with symptomatic brain metastases or active autoimmune disease are excluded.

ClinicalTrials.gov ID: NCT06627647

A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC With PD-L1 TPS ≥50%

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with newly diagnosed, metastatic KRAS G12C-mutant NSCLC and high PD-L1 expression (TPS ≥50%), randomizing them to pembrolizumab plus either MK-1084—a selective KRAS G12C inhibitor—or placebo as first-line treatment. Key exclusions include prior systemic therapy for metastatic disease, active CNS disease, and certain comorbidities.

ClinicalTrials.gov ID: NCT06345729